Breathe Well Live Well
Condition: Asthma
Interventions: Drug: CHF 5993 200/6/12.5 µg; Drug: CHF 1535 200/6 µg; Drug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
Sponsor: Chiesi Farmaceutici S.p.A.
Not yet recruiting – verified February 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
 MedIndia |
ICS/LABA combination therapy increases asthma-related pharmacy cost
News-Medical.net Researchers find inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination products are commonly used by patients with mild asthma, … Amoxicillin Allergy More Likely in Children |
View full post on asthma – Google News
|
GSK and Theravance announce combination ICS/LABA Phase II results in the …
MarketWatch (press release) Our ongoing collaboration with GSK includes the Phase III programmes in both COPD and asthma, which are already underway for Relovair and its components. … Theravance Announces Results From Phase II Study For Developmental Combination … |
View full post on asthma – Google News